SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated November 27, 2025, reports a transaction in the company's own shares conducted during the month of November 2025. The filing details a share repurchase executed on November 26, 2025, acting through BNP Paribas SA as the broker.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital structure changes via share buybacks rather than operational financial performance. Key metrics for the reported transaction include:
- Date of Purchase: November 26, 2025
- Shares Purchased: 170,733 ordinary shares
- Price Range: 1,794.50p (Low) to 1,819.50p (High)
- Volume-Weighted Average Price (VWAP): 1,807.55p
- Trading Venues: London Stock Exchange (XLON), CHIX, and BATE
- Treasury Share Holdings: 236,113,577 shares (post-transaction)
- Shares in Issue: 4,079,318,350 (excluding Treasury shares)
- Treasury Voting Rights: 5.79% of total voting rights
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes vs. Prior Period
This transaction is part of an existing buyback programme announced on September 30, 2025. Since the programme's inception on that date, GSK has purchased an aggregate of 10,648,733 ordinary shares. The filing does not provide comparative financial data against prior periods as it is a transactional report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section of the 2024 Annual Report on Form 20-F and the Q3 2025 Results.
Key Facts for Investor Verification
- Verify the total number of shares held in treasury (236,113,577) against the company's latest capitalization table.
- Confirm the 5.79% voting rights attribution for treasury shares for disclosure threshold calculations under FCA rules.
- Review the cumulative buyback volume of 10.65 million shares since September 30, 2025, to assess remaining programme capacity.
- Note that this filing does not contain operational financial results; refer to Form 20-F or quarterly results for revenue and earnings data.